GLABF (Gemina Laboratories) Shares Buyback Ratio %: -2.77 (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Gemina Laboratories Shares Buyback Ratio %?

Gemina Laboratories GLABF -27.59% Shares Buyback Ratio % is -2.77 as of Aug. 06, 2026. The stock has 2 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Gemina Laboratories's current shares buyback ratio was -2.77%.

Gemina Laboratories Shares Buyback Ratio % Related Terms

Gemina Laboratories Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Gemina Laboratories's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories Shares Buyback Ratio % Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Shares Buyback Ratio %
0.00 0.00 -45.96 0.00 -1.00

Gemina Laboratories Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.31 -0.38 -2.15 -0.22 0.00

Gemina Laboratories Shares Buyback Ratio % Calculation

Gemina Laboratories's Shares Buyback Ratio for the fiscal year that ended in Jan. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jan. 2024 ) - Shares Outstanding (EOP) (A: Jan. 2025 )) / Shares Outstanding (EOP) (A: Jan. 2024 )
=(73.326 - 74.060) / 73.326
=-1.00%

Gemina Laboratories's Shares Buyback Ratio for the quarter that ended in Oct. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jul. 2025 ) - Shares Outstanding (EOP) (A: Oct. 2025 )) / Shares Outstanding (EOP) (A: Jul. 2025 )
=(76.571 - 76.571) / 76.571
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -2.77 mean?
Gemina Laboratories (GLABF) has a Shares Buyback Ratio % of -2.77 as of Aug. 06, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Gemina Laboratories and its competitors.
Is Gemina Laboratories' Shares Buyback Ratio % too high?
Gemina Laboratories' current Shares Buyback Ratio % is -2.77.
How does Gemina Laboratories' Shares Buyback Ratio % compare to VRTX and REGN?
Gemina Laboratories' Shares Buyback Ratio % of -2.77 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Gemina Laboratories and its competitors. Gemina Laboratories's current Shares Buyback Ratio % is -2.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gemina Laboratories stock overvalued right now?
Gemina Laboratories (GLABF) has a current Shares Buyback Ratio % of -2.77. The current Shares Buyback Ratio % is -2.77. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Gemina Laboratories (GLABF), the current Shares Buyback Ratio % is -2.77 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gemina Laboratories Business Description

Address 3600 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.